Drug Profile
GB 21
Alternative Names: E92/114; W164Latest Information Update: 20 Sep 2006
Price :
$50
*
At a glance
- Originator Andrulis Pharmaceuticals
- Class Antineoplastics; Platinum complexes
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 20 Sep 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 08 Sep 1998 Profile reviewed
- 08 Sep 1998 No-Development-Reported for Cancer in USA (Unknown route)